The transition of marijuana from an illicit substance to a legal commodity has necessitated the development of rigorous regulatory and quality control frameworks. Unlike unregulated products, legal medical marijuana must undergo stringent laboratory testing for potency (cannabinoid profile) and purity. This includes screening for heavy metals, pesticides, residual solvents from extraction, and microbial contaminants like mold or salmonella.

In the United States and Europe, the regulatory landscape is fragmented, with varying standards for "Good Manufacturing Practices" (GMP). Technical insights into the seed-to-sale tracking systems and the standardized packaging requirements for child-resistance are found in the Legal Marijuana Market resource. These regulations ensure that patients receive a consistent product, which is essential for accurate clinical dosing.

As more jurisdictions move toward legalization, there is a push for international standardization. The "Certificate of Analysis" (COA) has become the gold standard for transparency, allowing clinicians to verify the exact chemical makeup of the product before recommending it to a patient. This regulatory oversight is what distinguishes the legal market from the "gray" or illicit markets, prioritizing consumer safety and public health.